ArticleBMC health services research2026
Trends in growth hormone utilization in Korea: a nationwide study from 2019 to 2023.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundGrowth hormone (GH) therapy is indicated for growth hormone deficiency (GHD) and selected growth-related conditions. In South Korea, both the supply and prescription of GH have increased steadily, drawing increased attention to national utilization patterns, particularly among children and adolescents. This study aimed to examine nationwide trends in GH injection supply and prescriptions in South Korea from 2019 to 2023 using Health Insurance Review and Assessment Service (HIRA) data.
methodsA nationwide cross-sectional analysis was conducted using supply data for 36 GH injection products and HIRA prescription claims from 2019 to 2023. Trends in GH supply and prescriptions were analyzed and stratified by age, sex, year, region, medical institution type, and medical department.
resultsGH injection supply increased steadily over the study period, with the total supply volume rising from 2,457,275 units in 2019 to 4,939,945 units in 2023. The number of patients and prescriptions also increased markedly, with annual prescriptions rising from 95,262 to 267,330 during the same period. The proportion of male patients showed a slight upward trend, from 43.7% in 2019 to 46.1% in 2023. Seoul consistently accounted for the largest share of GH supply (38.6% in 2023). Although tertiary hospitals remained the largest contributors, their relative share declined from 41.7% to 25.8%, while primary care clinics showed the most pronounced increase, rising from 7.2% to 24.1%.
conclusionsGH utilization in South Korea increased across all medical institution types, with a notable shift toward primary care settings. These findings highlight the importance of ongoing monitoring of GH utilization patterns and system-level discussions to support the appropriate and evidence-based use of GH therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.